UZ Leuven — Sponsor Intelligence | 72 EU Trials

Filter these 72 trials by condition, phase, country and more.

Open in Search →

72 Registered trials

41 Recruiting

22 Completed trials

6 Countries active

111 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 11 Phase II/III: 4 Phase II: 13 Phase I/II: 2 Phase III/IV: 6 Phase IV: 31 Phase I: 1 Phase I (Other): 4

Oversight events:

2 temporary halts 1 corrective measure across 2 trials

View oversight register →

100%

22 of 22 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Rheumatoid arthritis 2 Coronary artery disease 1 Acute myocardial infarction 1 Cardiac rehabilitation therapy 1 Colon cancer 1 Obesity 1 Breast cancer female 1 Malignant melanoma 1 Stress 1 Atrial fibrillation 1 Chronic rhinosinusitis with nasal polyps 1 Crohn's disease 1

Top IMPs

OXYTOCIN 6 [AL[18F]F]FAPI-74 3 SODIUM CHLORIDE 3 DEXAMETHASONE PHOSPHATE 2 DICLOFENAC SODIUM 2 ENZALUTAMIDE 2 GUSELKUMAB 2 SEMAGLUTIDE 2 [18F]ALF-NOTA-OCTREOTIDE 1 ABEMACICLIB 1 ABIRATERONE ACETATE 1 ALUMINIUM OXIDE, HYDRATED, ALUMINIUM OXIDE, MAGNESIUM HYDROXIDE 1

All trials

72 total

Enhancing social attunement in autism via interpersonal sensorimotor synchronization therapy combined with single-dose intranasal oxytocin a… Not authorised

2023-505253-41-00 Phase III 1 country OXYTOCIN
A single center study to evaluate the safety and tolerability of oral Azathioprine in patients with ADPKD Not authorised

2025-524313-86-00 Phase II 1 country AZATHIOPRINE
Comparison of two treatments (intrathecal baclofen pump and selective dorsal rhizotomy) for children with cerebral palsy who cannot walk Pending

2024-518822-33-01 Phase IV 2 countries BACLOFEN
Assessing Oxytocin's Role in Mitigating Psychosocial Stress in Breast Cancer Survivors Pending

2024-519383-40-00 Phase III 1 country OXYTOCIN
A phase 2, single arm, open label, study on the safety and feasibility of Liver Isolated Oxaliplatin (LIOX) delivered via arterial access de… Pending

2025-523261-25-00 Phase II 1 country OXALIPLATIN
Colonic Intramural Injections of Botulin toxin versus placebo to treat fragmented defecation and urgency after restorative total mesorectal … Pending

2025-524342-96-00 Phase II 1 country BOTULINUM TOXIN TYPE A
Randomized Evaluation of fleCAinide safety vs. STandard of care in patients with coronary artery disease and Atrial Fibrillation (ReCAST AF)… Pending

2025-525121-13-00 Phase IV 1 country AMIODARONE HYDROCHLORIDE; FLECAINIDE ACETATE; SOTALOL
The impact of beta-blocker therapy on quality of life and rehabilitation outcomes in patients after myocardial infarction with preserved eje… Pending

2026-525475-96-00 Phase IV 1 country
A neuropsychobiological approach to optimize patient selection for GLP-1-based pharmacotherapy for weight management across the binge eating… Pending

2026-526016-36-00 Phase IV 1 country SEMAGLUTIDE
Exploring the mechanistic link between the oxytocinergic system and mindfulness training Recruiting

2024-513482-39-00 Phase II 1 country OXYTOCIN
A novel fibroblast imaging biomarker and ultrahigh resolution PET to improve the diagnosis and follow-up of giant cell arteritis Recruiting

2025-523880-39-02 Phase II/III 1 country [AL[18F]F]FAPI-74
Guselkumab intervention and diet evaluation for pouchitis Recruiting

2025-521683-35-00 Phase IV 1 country GUSELKUMAB
Rapid Oral Switch in Infectious Endocarditis, the ROSIE study Recruiting

2025-524484-20-00 Phase IV 1 country AMOXICILLIN; AMOXICILLIN TRIHYDRATE, CLAVULANIC ACID; BENZYLPENICILLIN SODIUM; C…
The effect of CBD on sleep quality following late evening exercise Recruiting

2024-518609-17-00 Phase II 1 country CANNABIDIOL; SOFTISAN 378
Phase II RAINSPOT: a multicentric open label trial of Zolbetuximab-Paclitaxel-Ramucirumab in second line setting for CLDN18.2 positive gast… Recruiting

2025-521358-41-00 Phase II 1 country ZOLBETUXIMAB
The Impact of a Parasternal Block on Pain After Open-Heart Surgery: A Multicenter Clinical Trial Recruiting

2025-522135-34-00 Phase III/IV 1 country ROPIVACAINE HYDROCHLORIDE; SODIUM CHLORIDE
Oxytocin and attachment development: Looking beyond the expected? Recruiting

2024-518004-49-00 Phase I/II 1 country OXYTOCIN
Model-informed precision dosing during infliximab rescue therapy for patients with steroid-refractory acute severe ulcerative colitis: an ex… Recruiting

2023-503509-12-00 Phase IV 1 country INFLIXIMAB
Comparing postoperative recovery after vitrectomy using NSAID eyedrops versus steroid eyedrops Recruiting

2024-518807-23-00 Phase IV 1 country DEXAMETHASONE PHOSPHATE; DICLOFENAC SODIUM; TRIAMCINOLONE ACETONIDE
Prospective diagnostic performance of PET/CT using the novel fibroblast imaging tracer 18F-AlF-FAPI-74 versus standard of care 18F-FDG in in… Recruiting

2024-516464-28-00 Phase II/III 1 country [AL[18F]F]FAPI-74
BoNT in stroke Recruiting

2024-513158-32-01 Phase III/IV 1 country BOTULINUM TOXIN TYPE A - HAEMAGGLUTININ COMPLEX
Clindamycin for the treatment of infections: the influence of rifampicin and obesity on PK/PD target attainment Recruiting

2024-515872-12-00 Phase IV 1 country
Development of an optimized dosing regimen of ceftazidime-avibactam in critically ill patients treated with continuous renal replacement the… Recruiting

2023-505536-35-00 Phase IV 3 countries
Early Phase II Exploratory, Open-Label, Non-Randomized Study of Neoadjuvant Dostarlimab Monotherapy in Participants with Untreated T3-4N0-2 … Recruiting

2024-512499-36-00 Phase II 1 country DOSTARLIMAB

Showing 1–24 of 72 trials

← All sponsors A–Z